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A Simple, Mild and Straight forward Route for the
Synthesis of α-Ureidopeptidomimetics Using Cbz-Protected
Amino Acid Esters
Sagar N. Ramachandra, C. Srinivasulu, Basavaprabhu Hosamani, Santhosh L, and
Vommina V. Sureshbabu*[a]
The synthesis of α-ureidopeptidomimetics employing a simple,
mild and straight forward route starting from benzyloxy
carbonyl (Cbz-) protected amino acid esters in presence of 2-Cl
pyridine (2-chloropyridine) and Tf2O (triflic anhydride) in one-
pot is described. The in situ generated isocyanate intermediates
react with amino acid esters to yield the title compounds in
good yields (89-96%) and the protocol proved to be racemiza-
tion free.
Introduction
The modification of peptide backbone by making chemical
changes to the native peptide, or by conjugation of amino acid
building blocks has been important synthetic strategy to
induce stability towards peptidases with the preservation of
peptide biological potency.[1] Nowick and coworkers developed
artificial β-sheets containing diurea molecular scaffolds and
peptide strands.[2] A number of natural products and pharma-
cologically important compounds containing uriedo linkages
and ureidopeptidomimetics have also been described in the
literature.[3]
For the construction of peptidomimetics, insertion of
various functional groups on either terminus of amino acids is
essential. More often, the desired intermediates are prepared
starting from amino acids via N- and C-terminal modification/
substitution. Thus, amino group of an amino acid is replaced
with halide, azide, hydroxy, isonitrile, isocyanato and mercapto
groups which are then employed as key intermediates to
assemble a designed peptidomimetic.[4] In several cases,
substitutions are made on the N-terminus to install the
functionality of choice (as in the case of N-hydroxy, N-amino,
carbamoyl group) that enable to access the desired peptidomi-
metic.[5] Urea functionality has been regarded as peptide bond
surrogate and many ureidopeptidomimetics have proved to be
pharmaceutically important compounds.[6]
The isocyanate derivatives of amino acid esters are useful
precursors to ureidopeptidomimetics.[7] These compounds are
also useful chiral derivatizing agents and for the preparation of
chiral chromatographic media.[8] Classical method of prepara-
tion of isocyano ester involves use of gaseous phosgene on its
derivatives.[9]
There are various methods for the synthesis of unsym-
metrical urea tethered peptidomimetics. The widely employed
method involves the synthesis of amino acid azide followed by
its conversion to isocyanate via Curtius rearrangement followed
by reaction with amino component to get corresponding urea
tethered peptidomimetics.[10] The coupling reagents EDC/
HBTU,[11a] T3P,[11b] and CDI[11c] have been used for the prepara-
tion of acid azides, which later utilized for the synthesis of urea
tethered peptidomimetics. The Lossen rearrangement of amino
acid hydroxamates in presence of 1-propanephosphonic anhy-
dride (T3P) followed by reaction with amine also gives the
desired ureas.[11d] The isocyanates derived from hydrochloride
salts of amino acid esters and peptide esters have been
prepared from the corresponding amino component by
refluxing in toluene with purging of gaseous phosgene over a
period of several hours or by the addition of a solution of
phosgene in toluene either under biphasic conditions using
aqueous sodium carbonate solution or by using excess of
pyridine.[12–14] Triphosgene [bis(trichloromethyl)carbonate] is
preferred as an alternative over phosgene, though reported to
result in contaminants.[15] Thus, the application of the above
approaches, in principle, needs the conversion of α-amino
group of amino acid esters or peptide esters to isocyanates
which can be used directly or via carbamates to prepare
ureidopeptides. These methods, in general, involve multiple
steps and further require preparation of reagent, long reaction
time, and use of large excess of reagents. One of the three
commonly employed protected groups in peptide synthesis is
Cbz-protecting group. The Cbz-amino acids are crystalline, shelf
stable solids and are commercially available and cheap. The
Cbz group is stable under basic and acidic conditions, and can
be removed by catalytic hydrogenation or by strong acid.
However, the direct synthesis of α-ureidopeptides starting from
Cbz-protected amino acid esters has not yet arrived in the
literature. Therefore, the development of such a route would
be advantageous for the synthetic community. To the best of
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our knowledge, a facile, divergent one-pot route using in situ-
generated isocyanates for the synthesis of α-ureidopeptides
from Cbz-protected amino acid esters is the first report of its
kind. Trifluoromethanesulfonic (triflic) anhydride-pyridine con-
junction upon activation of amides has found to show
conversion to various functional groups on treatment with
suitable nucleophiles.[16] Inspired by the recent reports on the
reaction of Boc and Cbz-protected amines for the synthesis of
unsymmetrical ureas,[17,18] herein, we report the one-pot syn-
thesis of α-ureidopeptides from Cbz-protected amino acid
esters devoid of any coupling agents.
Results and Discussion
We investigated the preparation of α-ureidopeptides starting
from Cbz-protected amino acid esters in presence of suitable
base and triflic anhydride (Tf2O). In a typical experiment, to a
solution of Cbz-Val-OMe (1a) (1.0 equiv) in dry CH2Cl2, 2-
chloropyridine (2.5 equiv.) was added followed by slow
addition of Tf2O (1.5 equiv) and stirred at room temperature.
The formation of isocyanate was found to be completed in 15–
20 min as monitored by thin layer chromatography (TLC). To
the in situ formed isocyanate, was added a solution of Phg-OEt
(2a) (2.5 equiv.) to afford the title compound in 79% yield in
6 h. In order to enhance the yield, parallely, various bases and
their equivalence along with Tf2O and amino acid esters has
also been optimized to obtain suitable reaction conditions.
First, commonly employed bases N-methylmorpholine (NMM)
and N,N-diisopropylethylamine (DIEA) were employed. How-
ever these studies did not yield desired product in either case
(entries 2 and 3). When pyridine was employed as a base, the
product was obtained, albeit in 24% yield (entry 4). 2,6-Lutidine
also failed to improve the yield even when equivalence was
varied (entry 5 and 6). Significant improvement in yield (45%)
was noticed when 2-fluoropyridine was used as base (entry 7).
Alongside, various solvents viz. CH3CN, EtOAc, MeOH, THF and
CH2Cl2 were screened. Howbeit, no significant improvement in
yield was noticed among the solvents except CH2Cl2 and so
was found efficient for the formation of desired product (3a).
Finally 2-chloropyridine was employed with varying equivalen-
ces (entries 8–11), however the best result was obtained in
presence of 3.0 equiv. of 2-chloropyridine with 96% yield. Also,
the use of 1.5 equiv. of Tf2O in dry CH2Cl2 and 3.0 equiv. of
amino acid ester found to yield the desired product in good
yield in 6–10 h.
With the optimized reaction conditions in hand, the
generality of this one-pot procedure for the synthesis of α-
ureidopeptides was explored. The reaction turned out to be
tolerant of various Cbz-protected amino acid esters and amino
esters. The advantage of the current methodology is the mild
reaction conditions, which enable the isocyanate to react with
amine to form desired products. The title compounds were
obtained in high yields (89-96%).
Racemization studies were performed to check the optical
homogeneity of the compounds resulting from this protocol.
The RP-HPLC profiles were analyzed for the epimeric products
3d and 3d*. Compounds 3d and 3d* showed retention times
Table 1. Optimization of the reaction conditions for the synthesis of α-
ureidopeptides employing amino acid derivatives.
Entry Base (equiv.) Tf2O
(equiv.)
Amino acid ester
(equiv.)
Yield
(%)b
1 None 1.5 2.5 0
2 NMM (3.0) 2.0 3.0 0
3 DIEA (2.5) 1.5 3.0 nd
4 Pyridine (2.5) 2.0 3.0 24
5 2,6-Lutidine
(2.5)
1.5 2.5 29
6 2,6-Lutidine
(3.0)
2.0 3.0 31
7 2-F-Pyridine
(2.5)
1.5 3.0 45
8 2-Cl-Pyridine
(2.5)
1.5 2.5 79
9 2-Cl-Pyridine
(3.0)
1.5 3.0 96
10 2-Cl-Pyridine
(3.0)
2.0 3.0 86
11a 2-Cl-Pyridine
(3.0)
2.5 3.0 83
NMM=N-Methylmorpholine. DIEA=N,N-Diisopropylethylamine. aReaction
mixture stirred at 45 0C for 10 h. bYield obtained after column
chromatography. nd=not determined.
Scheme 1. Synthesis of urea tethered peptidomimetics through various
routes reported in literature.
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(Rt) 6.123 min and 4.376 min respectively. In supplement,
consciously prepared equimolar mixture of 3d and 3d*
showed distinct retention times of 6.262 and 4.433 min
respectively. These evidences from the analyses ensured that
the reaction does not suffer from racemization and hence the
protocol was racemization-free.
In the possible mechanism, initially 2-Cl-pyridine as a base
abstracts proton from the amide N  H and thereby facilitating
the π-electrons of the carbonyl group to add to one of the
sulfur atoms of triflic anhydride with the release of one
molecule of trifluorosulfonate. Thus formed imino triflate
intermediate then undergoes rearrangement with the assis-
tance of liberated sulfonates resulting in the formation of
corresponding amino acid ester isocyanate. Then the addition
of amino acid ester to this in situ generated isocyanate led to
the formation of desired α-ureidopeptides.
Conclusions
In conclusion, we have developed a simple and straight
forward route for the synthesis of α-ureidopeptides (without
any coupling agents) starting from Cbz-protected amino acid
ester and amino ester under mild reaction conditions, in
presence of 2-Cl pyridine and Tf2O. The protocol resulted in α-
ureidopeptides in good yields (89-96%). Also the protocol is
devoid of racemization.
Supporting Information Summary
Procedure for synthesis of α-ureidopeptidomimetics, HRMS, 1H,
13CNMR spectra and characterization data of compounds (3a-i),
and RP-HPLC data are appended in the supporting information.
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